Science
Pfizer vaccine may protect against new mutations of coronavirus
Owing to the evolution of the coronavirus, scientists have called for the continuous monitoring of changes in the virus for vaccine coverage
Covaxin: Last word on efficacy yet to be heard
Doubts raised over clinical trial mode as to why vaccine given permission without completion of human trials
Vaccine makers call approval a giant leap
SII has stockpiled around 5 crore dosages of the vaccine and aims to produce up to 10 crore per month by March next year
New coronavirus strain may replace the old one, say experts
The biggest worry is the status of the vaccines due to the emerging new strains
Bharat Biotech sends Phase-2 study results of Covaxin trial
Altogether, the data of human trials on 26,000 volunteers has to be submitted by the company to the subject committee
Genome sequencing takes a hit in India
Problems aplenty in importing chemicals
Experts call for molecular sequencing of the virus
Intensified vaccination programme most viable: Researchers
Serum Institute applies for emergency use authorisation for COVID-19 vaccine
The Pune-based company has collaborated with Oxford University and pharmaceutical company Astra Zeneca for making the vaccine
No severe safety event on Covid vaccine: AstraZeneca
There were 23,000 participants being assessed, who among them would be following two regimes of half dose and full dose
Oxford University COVID-19 vaccine 'encouraging' for older age groups
Older individuals are at disproportionate risk of severe COVID-19 and so any vaccine adopted for use must be effective in older adults